GlassScriptPhysician profile
George D Anastasio
NPI 1770508087
$24,028.19
in general payments reported to CMS, 2019-2025
70 companies · $2,981 in 2025
The $2,981 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,997 · 2020: $3,733 · 2021: $3,844 · 2022: $2,951 · 2023: $2,700 · 2024: $2,821 · 2025: $2,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,498 · Education: $4.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,497.52 |
| Education | $4.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,116.47 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $2,118.98 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $1,991.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,386.54 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $1,371.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,356.82 | 2019-2025 | |
| Lilly USA, LLC | $1,260.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,093.33 | 2019-2025 | Evenity, Prolia, Prolia |
| Sanofi-Aventis U.S. LLC | $1,013.03 | 2019-2025 | |
| Allergan, INC. | $886.70 | 2019-2020 | |
| Abbott Laboratories | $693.43 | 2019-2025 | Freestyle Libre 3, Id Now Instrument |
| Takeda Pharmaceuticals U.S.A., INC. | $597.27 | 2019-2025 | Glassia, Trintellix |
| Astellas Pharma US INC | $590.91 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $585.02 | 2019-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $475.60 | 2019-2025 | Xifaxan |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Anastasio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.